Table 2.

Review of Cases, Interventions, and Outcomes of Locally Invasive and Metastatic Conjunctival Melanoma Treated with Targeted Molecular Inhibitors

Author	Age (Years)	Sex	Clinical Indication	Management	Agent(s) Used	Toxicity	Response	Follow-Up (Months)
Griewank et al (2013)94	43	Male	Metastasis to muscle, lungs, brain	BRAF inhibitor	Dabrafenib	None	Partial	6
Weber et al (2013)28	45	Male	Metastasis to lymph nodes, subcutaneous tissue, lungs, bones	BRAF inhibitor	Vemurafenib	None	Mixed*	2
Dagi Glass et al (2016)31	61	Female	Locally advanced disease	BRAF/MEK inhibitors, then BRAF inhibitor alone, then anti-PD1, then again BRAF/MEK inhibitors	Dabrafenib/Trametinib, then Vemurafenib, then Pembrolizumab, then Vemurafenib/Cobimetinib	Nausea, vomiting	Nearly complete	23
Maleka et al (2016)32	53	Female	Orbital, parotid gland, lung and brain metastasis	BRAF inhibitor	Vemurafenib	Maculopapular rash	Partial	4
Pinto Torres et al (2017)34	56	Female	Metastasis to lymph nodes and oropharynx	BRAF inhibitor	Vemurafenib	Arthralgia, diarrhea, skin rash	Complete	52
Kiyohara et al (2019)38	71	Male	Local recurrence and metastasis to liver and vertebrae	BRAF inhibitor, then anti-PD1 and BRAF/MEK inhibitors	Vemurafenib, then Nivolumab and Dabrafenib/Trametinib	Erythema multiforme-like eruption, keratinous nodules on chest and scalp	Partial	30
	72	Male	Metastasis to lymph nodes	BRAF/MEK inhibitors	Dabrafenib/Trametinib	None	Complete	6
Demirci et al (2019)35	70	Female	Locally advanced disease	BRAF/MEK inhibitors	Dabrafenib/Trametinib	None	Substantial	15
Rossi et al (2019)40	70	Male	Metastasis to lymph nodes	BRAF/MEK inhibitors	Dabrafenib/Trametinib	Fever, elevated liver enzymes	Partial	11 months

Note: *In this case, the patient experienced initial regression of disease at 1 month, followed by progression at 2 months.